Skip to content
FearGreedChartHEALTH

Methodology

How the gauges are built

Every part, weight and limit of the healthcare readings, so you can check them yourself.

Why two gauges

Big pharma and biotech are moved by different things and often head in opposite directions. Pharma moves on patent expiries, dividends and leaders such as the GLP-1 weight-loss drugs. Biotech moves on trial results, access to funding and FDA decisions.

One combined score would average the two away. When pharma reads greed and biotech reads fear, that gap is the useful reading.

Pharma giants gauge

15 companies: LLY, NVO, JNJ, PFE, MRK, ABBV, BMY, AZN, GSK, NVS, ABT, AMGN, RHHBY, SNY and TAK.

Momentum · 50%

The average distance of each share price from its 125-day average. −15% scores 0 and +15% scores 100.

score = 50 + (average % above the 125-day average ÷ 15) × 50

Valuation · 25%

The middle price-to-earnings ratio of the group, from Finnhub. We use normalized earnings, which leave out one-off charges common in pharma, and fall back to the last 12 months only when needed. Ratios above 60 or below 5 are dropped as bad data. A ratio of 12 scores 100 and 28 scores 0, so richer valuations read as more greed.

score = 100 − (middle P/E − 12) × 5

Insider filings · 25%

How many of the 15 companies had an insider filing (SEC Form 4) in the past 30 days. It counts activity only: it doesn’t yet tell purchases from sales.

Biotech gauge

23 companies: 10 large and 13 smaller biotech names, plus the XBI and IBB funds for comparison.

Strength against biotech overall · 40%

The 90-day return of XBI, which weights every company equally and so leans to smaller names, minus that of IBB, which is dominated by the largest. −20 points scores 0 and +20 scores 100.

Distance from highs · 35%

How far the smaller biotech names sit below their 52-week highs on average. 50% below scores 0; at the high scores 100. Deep falls here often mean companies are short of cash and selling new shares.

Breadth · 15%

The share of all biotech names trading above their 50-day average.

New listings · 10%

Healthcare stock market listings (IPOs) in the past 30 days, from Finnhub, leaving out blank-cheque companies (SPACs). None scores 35, five score 80, eight or more score 95.

Health insurers

UNH, ELV, CI, HUM, CNC and CVS, compared with the XLV healthcare fund over 30 days, in five levels from Surging to Stressed. They are not a third gauge because they move on medical costs, Medicare rates and regulation rather than drug news. More on insurers

Mergers and FDA dates

Mergers: a full-text search of SEC 8-K filings for merger agreements, keeping drug, biotech and diagnostics companies that report signing (Item 1.01) or completing (Item 2.01) a deal. Deal values and premiums are not read from the filings.

FDA dates: advisory committee meetings come automatically from Federal Register notices; PDUFA decision dates are added by hand from company filings.

The history chart

The daily chart mixes two kinds of points. Live points are written each day after the close. Earlier points were rebuilt from price history with the same formulas: the price-based parts (momentum, strength against biotech, distance from highs, breadth) were recalculated for each day, while valuation, insider filings and new listings were held at today’s values. Where both exist for a date, the live point is used.

How often it updates

  • Gauges and the insurer comparison: every weekday after the US close.
  • Mergers: daily, from SEC EDGAR.
  • FDA meetings: daily, from the Federal Register.
  • Insider filings: daily, over a rolling 30 days.

What it doesn’t do

  • It doesn’t predict. The gauges describe how the market has been behaving, not what it will do.
  • It doesn’t rate single stocks. Lilly can rise while the pharma gauge reads fear.
  • It doesn’t cover every FDA date. The PDUFA list is short and hand-made.
  • It uses daily closes, not live prices.
  • Insider filings are counted, not classified, as purchases or sales.

Nothing here is investment advice.